BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 12164380)

  • 1. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
    Kreuter J; Shamenkov D; Petrov V; Ramge P; Cychutek K; Koch-Brandt C; Alyautdin R
    J Drug Target; 2002 Jun; 10(4):317-25. PubMed ID: 12164380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of apolipoproteins on dalargin transport across the blood-brain barrier.
    Shamenkov DA; Petrov VE; Alyautdin RN
    Bull Exp Biol Med; 2006 Dec; 142(6):703-6. PubMed ID: 17603675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticulate systems for brain delivery of drugs.
    Kreuter J
    Adv Drug Deliv Rev; 2001 Mar; 47(1):65-81. PubMed ID: 11251246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain.
    Michaelis K; Hoffmann MM; Dreis S; Herbert E; Alyautdin RN; Michaelis M; Kreuter J; Langer K
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1246-53. PubMed ID: 16554356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Transport of the hexapeptide dalargin across the hemato-encephalic barrier into the brain using polymer nanoparticles].
    Aliautdin RN; Petrov VE; Ivanov AA; Kreuter J; Kharkevich DA
    Eksp Klin Farmakol; 1996; 59(3):57-60. PubMed ID: 8974587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
    Kreuter J; Ramge P; Petrov V; Hamm S; Gelperina SE; Engelhardt B; Alyautdin R; von Briesen H; Begley DJ
    Pharm Res; 2003 Mar; 20(3):409-16. PubMed ID: 12669961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
    Alyautdin RN; Petrov VE; Langer K; Berthold A; Kharkevich DA; Kreuter J
    Pharm Res; 1997 Mar; 14(3):325-8. PubMed ID: 9098875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.
    Kreuter J; Hekmatara T; Dreis S; Vogel T; Gelperina S; Langer K
    J Control Release; 2007 Mar; 118(1):54-8. PubMed ID: 17250920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain.
    Kreuter J
    J Nanosci Nanotechnol; 2004 May; 4(5):484-8. PubMed ID: 15503433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro.
    Alyaudtin RN; Reichel A; Löbenberg R; Ramge P; Kreuter J; Begley DJ
    J Drug Target; 2001 Jun; 9(3):209-21. PubMed ID: 11697206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles).
    Kreuter J; Alyautdin RN; Kharkevich DA; Ivanov AA
    Brain Res; 1995 Mar; 674(1):171-4. PubMed ID: 7773690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circadian phase-dependent antinociceptive reaction in mice determined by the hot-plate test and the tail-flick test after intravenous injection of dalargin-loaded nanoparticles.
    Ramge P; Kreuter J; Lemmer B
    Chronobiol Int; 1999 Nov; 16(6):767-77. PubMed ID: 10584177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells.
    Ramge P; Unger RE; Oltrogge JB; Zenker D; Begley D; Kreuter J; Von Briesen H
    Eur J Neurosci; 2000 Jun; 12(6):1931-40. PubMed ID: 10886334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles].
    Aliautdin RN; Petrov VE; Langer K; Berthold A; Kreuter J; Kharkevich DA
    Eksp Klin Farmakol; 1998; 61(1):17-20. PubMed ID: 9575405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections.
    Schröder U; Sabel BA
    Brain Res; 1996 Feb; 710(1-2):121-4. PubMed ID: 8963650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier.
    Schroeder U; Sommerfeld P; Sabel BA
    Peptides; 1998; 19(4):777-80. PubMed ID: 9622035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
    Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
    J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats.
    Ambruosi A; Yamamoto H; Kreuter J
    J Drug Target; 2005 Dec; 13(10):535-42. PubMed ID: 16390814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle technology for delivery of drugs across the blood-brain barrier.
    Schroeder U; Sommerfeld P; Ulrich S; Sabel BA
    J Pharm Sci; 1998 Nov; 87(11):1305-7. PubMed ID: 9811481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB).
    Kreuter J
    J Microencapsul; 2013; 30(1):49-54. PubMed ID: 22676632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.